Neukio Biotherapeutics

Executive Summary

Neukio Biotherapeutics is a Shanghai-based preclinical/Phase 1 biotechnology company pioneering next-generation engineered cell therapies for oncology, with a focus on CAR-T and CAR-NK platforms. Founded in 2021, the company aims to overcome key limitations of current cell therapies, including poor solid tumor penetration and cytokine release syndrome, by developing novel engineering strategies to enhance efficacy and safety. While still in early clinical stages, Neukio's innovative pipeline targets difficult-to-treat cancers and leverages proprietary technology to improve tumor microenvironment access and reduce off-target toxicity. The company's progress through Phase 1 trials will be a critical indicator of its platform's potential.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 trial for lead CAR-T candidate in solid tumors70% success
• Q3 2026Presentation of preclinical data for next-generation CAR-NK platform at major conference80% success
• 2027Strategic partnership or licensing deal for solid tumor cell therapy technology50% success